Wellcome Trust Case Control Consortium

Home
WTCCC1 WTCCC2 WTCCC3
Information
Overview WTCCC3 studies
WTCCC3 studies
Anorexia Nervosa Host control of HIV-1 Renal Transplant Dysfunction Pre-Eclampsia Primary Biliary Cirrhosis
Press & publications
Press Release: 28/09/2005 Press Release: 06/06/2007 Publications and presentations
Data access
Access to data Approved Applications CDAC members Data formats FAQ
Open access
Available software
Participant access
Participant Login
Contact
Feedback and queries

Wellcome Trust Case Control Consortium 3

To build further on the success of the GWAS approach demonstrated by the WTCCC, the Wellcome Trust has provided support for a further round of GWA studies in January 2009. These include 5 WTCCC-collaborative studies to be carried out in WTCCC3 and 5 independent studies, across a range of diseases. Many of the studies represent major international collaborative networks that have together assembled large sample collections.

WTCCC3 will perform genome-wide association studies in the following 4 disease conditions: primary biliary cirrhosis, anorexia nervosa, pre-eclampsia in UK subjects, and the interactions between donor and recipient DNA related to early and late renal transplant dysfunction. The WTCCC3 will also carry out a pilot in a study of the genetics of host control of HIV-1 infection. Over 40,000 samples will be analysed using the Illumina 660K chip. The WTCCC3 will utilise the 6,000 control genotypes generated by the WTCCC2.